Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer.

Kenneth L KehlShihao YangMark M AwadNathan PalmerIsaac S KohaneDeborah Schrag

Published in: Cancer immunology, immunotherapy : CII (2019)

Pre-existing autoimmune disease was not associated with time to any hospitalization after initiating ICI therapy, but it was associated with a modest increase in hospitalizations with irAE diagnoses and with corticosteroid treatment.

Keyphrases

multiple sclerosis
dna damage
papillary thyroid
drug induced
cell cycle
stem cells
squamous cell
combination therapy
oxidative stress
young adults